General AML

A retrospective comparative study of haploidentical versus HLA-matched allogeneic hematopoietic stem cell transplantation in…

Emily Smith , Feb 22, 2019

IDH1/2

FDA grants ivosidenib (Tibsovo®) priority review for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid…

Philippa Redondo , Feb 21, 2019

General AML

Guadecitabine therapy following treatment failure with azacitidine in patients with acute myeloid leukemia

Philippa Redondo , Feb 21, 2019

General AML,   IDH1/2

Enasidenib found to induce molecular remissions in IDH2-mutated, relapsed/refractory acute myeloid leukemia

Zara Kassam , Feb 20, 2019

General AML

CAR T Cell Meeting 2019 | CAR T-cell therapy for acute myeloid leukemia

Philippa Redondo , Feb 19, 2019

General AML

The FLAGM regimen in younger adult patients with relapsed or refractory acute myeloid leukemia

Philippa Redondo , Feb 14, 2019

General AML,   IDH1/2,   & 1 more

ASH 2018 | Practice changing abstracts in acute myeloid leukemia 

Andrew Wei Charles Craddock Gail J. Roboz Gert Ossenkoppele , Feb 13, 2019

General AML

Venetoclax monotherapy in elderly patients with secondary acute myeloid leukemia

Philippa Redondo , Feb 12, 2019

General AML

The benefit of high dose mitoxantrone-based (“5 + 1”) induction chemotherapy in elderly patients with newly diagnosed…

Emily Smith , Feb 8, 2019

General AML

Real-world experience of non-intensive regimens in elderly patients with acute myeloid leukemia

Philippa Redondo , Feb 7, 2019